Compile Data Set for Download or QSAR
Report error Found 82 Enz. Inhib. hit(s) with all data for entry = 10278
TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524438(US11168083, Example 37)
Affinity DataEC50:  3.00E+3nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524448(2-((2S,4R)-4-amino-1-(6- chloroimidazo[1,2-a]pyrid...)
Affinity DataEC50: <100nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524447(2-((2S,4R)-4-amino-1-(6- chloroimidazo[1,2-a]pyrid...)
Affinity DataEC50:  550nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524446(2-((2S,4R)-4-amino-1-(5- chlorobenzo[d]thiazole-2-...)
Affinity DataEC50: <100nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524445(2-((2S,4R)-4-amino-1-(5- chlorobenzo[b]thiophcne-2...)
Affinity DataEC50:  550nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524444(2-((2S,4R)-4-amino-1-(3- chlorobenzo[b]thiophene-6...)
Affinity DataEC50:  7.50E+3nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524443(2-((2S,4R)-4-amino-1-(6- chloroquinoline-2-carbony...)
Affinity DataEC50: <100nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524442(2-((2S,4R)-4-amino-1-(3- chloroquinoline-6-carbony...)
Affinity DataEC50:  550nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524441(2-((2S,4R)-1-(2-naphthoyl)-4- aminopyrrolidin-2-yl...)
Affinity DataEC50:  3.00E+3nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524440(US11168083, Example 39)
Affinity DataEC50:  7.50E+3nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524439(US11168083, Example 38)
Affinity DataEC50: >9.90E+3nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524449(2-((2S,4R)-4-amino-1-(6- chloroimidazo[1,2-a]pyrid...)
Affinity DataEC50:  550nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524437(2-((2S,4S)-4-amino-1-(6- chloroimidazo[1,2-a]pyrid...)
Affinity DataEC50: <100nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524436(2-((2S,4R)-4-acetamido-1-(6- chloroimidazo[1,2-a]p...)
Affinity DataEC50:  3.00E+3nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524435(US11168083, Example 34)
Affinity DataEC50: >9.90E+3nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524402(US11168083, Example 33)
Affinity DataEC50:  3.00E+3nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524434(2-((2S,4R)-4-amino-1-(6- chloroimidazo[1,2-a]pyrid...)
Affinity DataEC50: >9.90E+3nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524433(N-((S)-3-(1H-indol-3-yl)-1- (methylamino)-1-oxopro...)
Affinity DataEC50: >9.90E+3nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524432(N-((S)-3-(1H-imidazol-4-yl)-1- (methylamino)-1-oxo...)
Affinity DataEC50: >9.90E+3nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524431((S)-2-(2-((2S,4R)-4-amino-1-(6- chloroimidazo[1,2-...)
Affinity DataEC50: >9.90E+3nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524430(2-((2S,4R)-4-amino-1-(6- chloroimidazo[1,2-a]pyrid...)
Affinity DataEC50:  7.50E+3nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524458(2-((2S,4R)-4-amino-1-(6- chloroimidazo[1,2-a]pyrid...)
Affinity DataEC50:  7.50E+3nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524467(2-((2S,4R)-4-amino-1-(2- chloroquinoline-6-carbony...)
Affinity DataEC50:  3.00E+3nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524466(2-((2S,4R)-4-amino-1-(6- chloroquinoline-3-carbony...)
Affinity DataEC50:  550nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524465(2-((2S,4R)-4-amino-1-(6- methylbenzo[b]thiophene-2...)
Affinity DataEC50:  550nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524464(2-((2S,4R)-4-amino-1-(5- (trifluoromethyl)benzo[b]...)
Affinity DataEC50:  550nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524463(2-((2S,4R)-4-amino-1-(4- chlorobenzo[b]thiophene-2...)
Affinity DataEC50:  3.00E+3nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524462(2-((2S,4R)-4-amino-1-(6- chlorobenzo[b]thiophene-2...)
Affinity DataEC50:  550nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524461(2-((2S,4R)-4-amino-1-(5,6- dichlorobenzo[b]thiophe...)
Affinity DataEC50:  550nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524460(2-((2S,4R)-4-amino-1-(6- chloroimidazo[1,2-a]pyrid...)
Affinity DataEC50: <100nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524459(2-((2S,4R)-4-amino-1-(6- chloroimidazo[1,2-a]pyrid...)
Affinity DataEC50: >9.90E+3nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524429(2-((2S,4R)-4-amino-1-(6- chloroimidazo[1,2-a]pyrid...)
Affinity DataEC50: >9.90E+3nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524414(US11168083, Example 57 | 2-((2S,4R)-4-amino-1-(6- ...)
Affinity DataEC50:  3.00E+3nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524456(2-((2S,4R)-4-amino-1-(6- chloroimidazo[1,2-a]pyrid...)
Affinity DataEC50: >9.90E+3nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524403(2-((2S,4R)-4-amino-1-(6- chloroimidazo[1,2-a]pyrid...)
Affinity DataEC50:  550nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524455(2-((2S,4R)-4-amino-1-(6- chloroimidazo[1,2-a]pyrid...)
Affinity DataEC50:  3.00E+3nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524454(2-((2S,4R)-4-amino-1-(6- chloroimidazo[1,2-a]pyrid...)
Affinity DataEC50: <100nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524453(2-((2S,4R)-4-amino-1-(6- chloroimidazo[1,2-a]pyrid...)
Affinity DataEC50: >9.90E+3nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524452(2-((2S,4R)-4-amino-1-(6- chloroimidazo[1,2-a]pyrid...)
Affinity DataEC50: <100nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524451(2-((2S,4R)-4-amino-1-(6- chloroimidazo[1,2-a]pyrid...)
Affinity DataEC50:  7.50E+3nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524450(2-((2S,4R)-4-amino-1-(6- chloroimidazo[1,2-a]pyrid...)
Affinity DataEC50: <100nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524428(N-((S)-6-acetamido-1-(methylamino)- 1-oxohexan-2-y...)
Affinity DataEC50: >9.90E+3nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524402(US11168083, Example 33)
Affinity DataEC50:  3.24E+3nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524403(2-((2S,4R)-4-amino-1-(6- chloroimidazo[1,2-a]pyrid...)
Affinity DataEC50:  15nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524404(2-((2R,4R)-4-amino-1-(6- chloroimidazo[1,2-a]pyrid...)
Affinity DataEC50:  3.00E+3nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524405(2-((2R,4R)-4-amino-1-(6- chloroimidazo[1,2-a]pyrid...)
Affinity DataEC50: >9.90E+3nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524406(2-((R)-1-(6-Chloroimidazo[1,2-a]pyridine-2-carbony...)
Affinity DataEC50: >9.90E+3nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524407(US11168083, Example 4)
Affinity DataEC50: >9.90E+3nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524408(2-((2R,4R)-4-acetamido-1-(6- chloroimidazo[1,2-a]p...)
Affinity DataEC50: >9.90E+3nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM524409(2-((2R,4S)-4-amino-1-(6- chloroimidazo[1,2-a]pyrid...)
Affinity DataEC50:  3.00E+3nMAssay Description:Plasma Kallikrein: The example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
Go to US Patent

Displayed 1 to 50 (of 82 total ) | Next | Last >>
Jump to: